| Price | 65.00p on 02-03-2026 at 12:35:08 |
|---|---|
| Change | -2.50p -3.7% |
| Buy | 67.00p |
| Sell | 63.00p |
| Last Trade: | Sell 500.00 at 64.60p |
| Day's Volume: | 1,193,477 |
| Last Close: | 67.50p |
| Open: | 66.50p |
| ISIN: | GB00BYYW9G87 |
| Day's Range | 64.00p - 66.50p |
| 52wk Range: | 27.25p - 83.20p |
| Market Capitalisation: | £284.46m |
| VWAP: | 65.15592p |
| Shares in Issue: | 437.63m |
Sector: Medicine and Biotech
Listed In: FTSE AIM All-Share,
Avacta Group (AVCT) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Sell* | 500 | 64.60p | Ordinary |
12:22:51 - 02-Mar-26 |
| Sell* | 531 | 64.5968p | Ordinary |
12:20:55 - 02-Mar-26 |
| Sell* | 432 | 64.60p | Ordinary |
12:20:18 - 02-Mar-26 |
| Sell* | 1,567 | 63.825p | Ordinary |
12:19:31 - 02-Mar-26 |
| Sell* | 10,000 | 64.64p | Ordinary |
12:17:36 - 02-Mar-26 |
| Sell* | 560 | 64.747p | Ordinary |
12:16:17 - 02-Mar-26 |
| Sell* | 1,375 | 63.75p | Ordinary |
12:12:05 - 02-Mar-26 |
| Sell* | 6,555 | 64.80p | Ordinary |
12:07:35 - 02-Mar-26 |
| Sell* | 7,921 | 64.4143p | Ordinary |
12:06:48 - 02-Mar-26 |
| Sell* | 4,653 | 64.84p | Ordinary |
12:04:49 - 02-Mar-26 |
Avacta Group (AVCT) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 24th Feb 2026 7:00 am | RNS | PreCISION payload delivery advantage over ADC |
| 18th Feb 2026 7:00 am | RNS-R | Avacta to Participate in Conference March 2026 |
| 9th Feb 2026 7:00 am | RNS | Appointment of CSO |
| 3rd Feb 2026 7:00 am | RNS | Faridoxorubicin Program Clinical Updates |
| 21st Jan 2026 7:00 am | RNS | FDA Clearance of IND Application for AVA6103 |
| 20th Jan 2026 7:01 am | RNS | Year-end trading update |
| 20th Jan 2026 7:00 am | RNS | Appointment of Nominated Adviser & TVR |
| 18th Dec 2025 7:00 am | RNS-R | Avacta reports new AVA6103 pharmacology data |
| 17th Dec 2025 7:00 am | RNS | Faridoxorubicin Phase 1b SGC data |
| 8th Dec 2025 7:00 am | RNS | Preliminary Data in Faridoxorubicin Phase 1b Trial |
